They said they used placebo treatments several times a month, and usually
described the pill or injection as “a potentially beneficial medicine not
typically used for your condition.” …
the system is able to sequence parts of the genome that contain many repeated
letters, which are virtually impossible to read now. By next year, the company
hopes to be selling sequencing machines. …
Eleven states that were not part of the initial 32-state probe have also filed
lawsuits over the atypical antipsychotic medication, which the company launched
in 1996. …
scientists in the company and collaborators in the US and Canada found that the
drug was transported rapidly across the blood-brain barrier and into the
functional part of the brain, the parenchyma. …
There’s nothing more sacred than the physician-patient relationship, and we
physicians have the responsibility to make sure nothing gets in the way of that
relationship–or even appears to get in the way.” …
the FDA warned that it would probably start missing deadlines because of a
staffing crunch. And observers have commented that the agency seems to be
hesitant at the approval trigger, perhaps because it’s gun-shy after a variety
of high-profile drug safety problems. …
Synthetic biology could be used to create new drugs and medical devices,
solve ecological problems and even create new organisms. …
“Patients with chronic neurodegenerative diseases frequently have many risk
factors for vitamin D insufficiency,” including advancing age, obesity,
avoidance of sun exposure, residence in northerly latitudes and having darker
skin. …
“Significantly more patients with style=”BACKGROUND: none transparent scroll repeat 0% 0%; CURSOR: hand; BORDER-BOTTOM: #0066cc 1px dashed”>Parkinson’s
disease [55 percent] had insufficient vitamin D than did controls [36
percent] or patients with Alzheimer’s
disease [41 percent],” the researchers wrote. …
1 ,25-dihydroxyvitamin D3 (1,25(OH)2 D3 ), which is the biologically active form
of vitamin D, has anti-inflammatory effects and can prevent experimental
Parkinson’s disease (PD). …